IMVT - Immunovant

-

$undefined

N/A

(N/A)

Immunovant NasdaqGS:IMVT Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Location: 320 West 37th Street, New York, NY, 10018, United States | Website: https://immunovant.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

2.082B

Cash

374.7M

Avg Qtr Burn

-81.23M

Short % of Float

33.30%

Insider Ownership

58.74%

Institutional Own.

56.33%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Data readout

Phase 3

Update

Phase 3

Update

IMVT-1402 Details
Rheumatoid arthritis

Phase 2b

Data readout

IMVT-1402 Details
Graves’ disease

Phase 2b

Data readout

Batoclimab (IMVT-1401) Details
Chronic inflammatory disorder

Phase 2b

Update

IMVT-1402 Details
Sjögren’s Disease (SjD)

Phase 2

Initiation

IMVT-1402 Details
Autoimmune disease, Warm autoimmune hemolytic anemia

Phase 1

Update

Batoclimab (IMVT-1401) Details
Warm autoimmune hemolytic anemia

Failed

Discontinued